HDT Bio

Coming – September 15

Keeping Cancer from Coming Back: The Promise of Immune Maintenance

Date and Time

September 15

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

For many breast cancer survivors, their greatest fear comes down to one word: relapse.

Modern treatments for HER2-positive breast cancer have become remarkably effective at bringing the disease under control. But even when scans are clear, microscopic cancer cells can remain behind, creating the possibility that the disease will eventually return. HDT Bio is developing a new approach aimed at this critical period: an immune-maintenance therapy designed for the years after successful treatment.

HDT-501 is an off-the-shelf cancer vaccine designed to train the immune system’s T cells to recognize HER2-positive cancer cells and potentially maintain pressure on any cancer that remains. Unlike chemotherapy or today’s HER2-targeted drugs, the goal is to create lasting immune memory, giving the body its own surveillance system to help keep the disease under control.

Recent Phase 3 success from Merck and Moderna provides important validation that RNA-based cancer vaccines can reduce recurrence in cancer patients. HDT is taking that concept in a different direction, using its self-amplifying RNA technology and LION delivery system to create a standardized vaccine designed for repeat dosing over an extended period. HDT’s platform has already been used in more than 6,000 people, and the first HDT-501 cancer patient is targeted to be dosed in Q4 2026, with initial human immune-response data expected in Q2 2027.

Join HDT Bio leaders for an executive briefing exploring how the company hopes to turn the immune system into a long-term line of defense against cancer recurrence, creating a potential immune-maintenance therapy for the years after successful treatment.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.